A relatively large phase II randomized double-blind study, Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF) [103], enrolled 144 patients (125 of whom completed the study) with ischemic cardiac injury and New York Heart Association (NYHA) class I-III symptoms of heart failure. This evidence concerns the gene KIT and heart failure.